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Abstract
In this study we investigated whether polymorphisms in the folate pathway influenced the risk of childhood acute
lymphoblastic leukemia (ALL) or the survival rate of the patients. For this we selected and genotyped 67 SNPs in 15 genes in
the folate pathway in 543 children with ALL and 529 controls. The results were evaluated by gender adjusted logistic
regression and by the Bayesian network based Bayesian multilevel analysis of relevance (BN-BMLA) methods. Bayesian
structure based odds ratios for the relevant variables and interactions were also calculated. Altogether 9 SNPs in 8 genes
were associated with altered susceptibility to ALL. After correction for multiple testing, two associations remained
significant. The genotype distribution of the MTHFD1 rs1076991 differed significantly between the ALL and control
population. Analyzing the subtypes of the disease the GG genotype increased only the risk of B-cell ALL (p = 3.5261024;
OR = 2.00). The GG genotype of the rs3776455 SNP in the MTRR gene was associated with a significantly reduced risk to ALL
(p = 1.2161023; OR = 0.55), which resulted mainly from the reduced risk to B-cell and hyperdiploid-ALL. The TC genotype of
the rs9909104 SNP in the SHMT1 gene was associated with a lower survival rate comparing it to the TT genotype (80.2% vs.
88.8%; p = 0.01). The BN-BMLA confirmed the main findings of the frequentist-based analysis and showed structural
interactional maps and the probabilities of the different structural association types of the relevant SNPs especially in the
hyperdiploid-ALL, involving additional SNPs in genes like TYMS, DHFR and GGH. We also investigated the statistical
interactions and redundancies using structural model properties. These results gave further evidence that polymorphisms in
the folate pathway could influence the ALL risk and the effectiveness of the therapy. It was also shown that in gene
association studies the BN-BMLA could be a useful supplementary to the traditional frequentist-based statistical method.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most frequent
haematopoetic malignancy in childhood worldwide [1], and also
in Hungary with about 60–80 new cases registered a year
(Hungarian Children Cancer Registry). In the last years several
genome wide and candidate gene association studies have tried to
explore the genetic background of the disease, and revealed a
number of genes and genetic variations, which might influence the
risk of the disease or the response to the therapy [2,3]. But these
results are often inconsistent and require further studies for
confirmation.
It is well known that genetic alterations of genes in DNA
synthesis or in DNA methylation could be a first step for
haematopoetic (lymphoid) malignant cell production [4,5]. It is
necessary to maintain the adequate concentration of folate
(tetrahidrofolate-THF) because folate provides a methyl group
for the proper DNA synthesis, moreover for homocysteine in the
methionine cycle, which is important in the DNA methylation
process [6,7]. Genetic variations of genes encoding pivotal
regulator and transport enzymes of the folate cycle (e.g. MTHFD1,
MTRR, MTR, MTHFR, DHFR, GGH, SLCO1B1) could influence
the available folate in the cells, and therefore might alter the
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susceptibility to ALL and the response to the therapy [7–12]. The
objective of this study was to investigate, whether genetic
polymorphisms in genes related to folate metabolic pathway
influence the risk to childhood ALL. On the other hand, as the
folate pathway is one of the main targets of the ALL chemotherapy
we also studied, whether these variations influence the overall and
event-free survival of the patients after the therapy. For this, we
selected 67 SNPs in 15 genes (DHFR, MTHFD1, MTHFR, MTRR,
MTR, SHMT1, TYMS, ABCB1, FPGS, GGH, GSTP1, SLCO1B1,
SLC19A1, SLC22A8, TPMT) in the folate metabolic pathway
(Figure 1 and Table S1).
Recently, several methods have been described and used for
evaluating multiple interactions in multifactorial diseases (for the
comparison of methods capable of capturing interactions see
[13,14]. In the present study, for the statistical analysis we applied
a traditional frequentist method (logistic regression), a multifactor
dimensionality reduction (MDR, [15]) tool and a Bayesian
statistical methodology, named Bayesian network based Bayesian
multilevel analysis of relevance (BN-BMLA), which extends
association analysis by estimating posteriors [16–18]of strong
relevance. By analyzing the data with BN-BMLA we intend to
refine the dependency relationships of factors, e.g. we investigate
whether a variable is directly relevant or its association is only
mediated.BN-BMLA was recently extended with Bayesian effect
size estimation providing a hybrid measure, the Bayesian structure
based odds ratio, which characterizes the parametric and strong
relevance aspects of factors [19].
In previous studies, we showed that the Bayesian networks offer
a rich language in the Bayesian statistical framework for the
representation of relevance types, including causal, acausal, and
multitarget aspects. We demonstrated that BN-BMLA can be a
useful supplementary to the traditional frequentist statistical
methods in gene association studies [20,21].
Methods
Study population
The study population consisted of 543 childhood acute
lymphoid leukemia (ALL) patients of Hungarian (Caucasian)
origin treated according to the ALL Berlin-Frankfurt-Mu¨nster
(BFM) 90, 95 or ALL IC-BFM 2002 chemotherapy protocols in
ten Hungarian centres. The patients were diagnosed with ALL
between 1990 and 2010. See more details about the characteristics
of patients in Table 1. The median age of ALL patients was 5.1 (1–
18) years at diagnosis. Peripheral blood samples were taken from
children with ALL in remission phase. Only those samples were
Figure 1. Schematic overview of the intracellular folate pathway. Key molecules and derivatives of the pathway are denoted as ovals,
regulatory enzymes as rectangles, affected DNA mechanisms as double rectangles. Genetic polymorphisms are showed in rectangles only where
significant results were found. dUMP=Deoxyuridine monophosphate, dTMP=Deoxythimidine monophosphate, Vit.B12= Vitamin B12, SAM= S-
adenosylmethionine, SAH= S-adenosylhomocysteine, TIMP= Thioinosine monophosphate, MetTIMP=Methyl-thioinosine monophosphate, AICAR-
T =AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) formyltransferase, GART=GAR (glycinamide ribonucleotide) formyltransferase.
doi:10.1371/journal.pone.0069843.g001
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involved in the study, where the normal leukocyte cell count
was$5 G/l measured by flow cytometry. In fact, we analyzed only
normal leukocytes and germline polymorphisms. There is no
significant difference in the distribution of age groups or genders
or ALL-immunophenotypes between the whole ALL children
population in the Hungarian Children Cancer Registry and our
sample collection.
Risk group stratifications were determined according to the
study protocols.
The 529 control patients (median years of age 12.5 (1.5–59)) of
the same ethnicity and from the same geographical region as the
patients were randomly selected from healthy blood donors and
from minor outpatients from the Orthopaedic Department in the
Budai Children’s Hospital, and from the Urological Department
of Heim Pal Pediatric Hospital, Budapest. None of the controls
have had childhood ALL or any other types of cancers previously.
Written informed consent was obtained from the study
participants or from the next of kin, caretakers, or guardians on
the behalf of the minors/children participants involved in the
study. All the associated documents have been stored. The study
was conducted according to the principles expressed in the
Declaration of Helsinki and the whole study including the
informed consent procedure were approved by the Hungarian
Scientific and Research Ethics Committee of the Medical
Research Council (ETT TUKEB; Case No.:8-374/2009-
1018EKU 914/PI/08.)
Genes and polymorphisms
Based on the relevant scientific publication results (candidate
gene association and GWA studies) and the dbSNP database of the
National Center for Biotechnology Information (NCBI; www.ncbi.
nlm.nih.gov. Accessed: 2013 Jun 20.) we selected and genotyped
67 single nucleotide polymorphisms in 15 key genes encoding the
main enzymes directly (MTHFR, MTRR, MTHFD1) or
indirectly (TPMT, GSTP1) involved in the folate cycle through
which the DNA synthesis, the DNA methylation and repair
mechanisms can be regulated (Table 2).
The criteria of the SNP selection were the minor allele
frequency$10% in Caucasian populations, their estimated func-
tionality (missense, UTR, intron) or relevant results published
previously in the scientific literature [8,11,12,22–35].
Two of the selected SNPs were monomorphic and one of them
did not meet the requirements of Hardy-Weinberg Equilibrium,
and hence 64 single nucleotide polymorphisms were involved in
the analyses.
Genotyping
The genomic DNA of ALL patients was obtained from
peripheral blood in a retrospective manner using QIAmp DNA
Blood Maxi Kit (Qiagen, Hilden, Germany). The healthy control
DNA was isolated with iPrep PureLink gDNA Blood Kit, iPrep
Purification Instrument (Invitrogen, Life Technologies Co., Grand
Island, USA).
Single nucleotide polymorphisms (SNPs) were genotyped by
Sequenom iPLEX Gold MassARRAY technology at the McGill
University and Ge´nome Que´bec Innovation Centre, Montre´al,
Canada. Only SNPs with genotyping call rate over 90% were
included in the analysis.
Statistical analysis
Frequentist statistical analysis. Gender adjusted logistic
regression model was applied to obtain odds ratios (ORs) and 95%
confidence intervals (CIs) to estimate risks for each polymorphism
to childhood ALL in the case-control data. Calculation of the
genotype frequency and the allele positivity was performed by
IBM SPSS Statistics software, version 21.0., and the allele
frequency was analysed by Medcalc Version 12.4.0.
The statistical analyses were performed not only for the overall
ALL population but also for the clinical subtypes (B-, T-cell and
hyperdiplod (HD)-ALL).
The Hardy-Weinberg equilibrium analysis was carried out by
x2 goodness-of-fit test through an online application (http://ihg.
gsf.de/cgi-bin/hw/hwa1.pl. Accessed: 2013 Jun 20. (see Table
S2).
Multiple testing corrections were performed using the Benja-
mini-Hochberg false discovery rate (FDR) method with type I
error rate of 5% (p#1,21E-03) [36,37]. Thus, ’’p’’ values,0.05
that could not reach the significance threshold (p#1.21E-03) of the
false discovery rate of 5%, were called nominally significant.
The statistical power was calculated by R, using an own
implementation of the Genetic Power Calculator of Purcell and
Sham [38]. The power calculations were adjusted using the same
hypothesis correction method as described above (a= 1,21E-03).
We calculated the power for the estimated allele frequencies and
ORs for all SNPs (see Figure S3). We also performed a standard
power calculation for different genetic models in our sample
groups for SNPs with typical minor allele frequencies (see Figure
S4). For example, in case of B-cell ALL, a SNP with minor allele
frequency of 0.4 and with a recessive genotype relative risk of 2
would result in a power of 0.75 using a recessive genetic model.
Linkage disequilibrium and haplotypes were calculated with
Haploview version 4.2. Odds ratios for haplotypes were obtained
by MedCalc 12.4.0 software.
The survival analysis was carried out with IBM SPSS Statistics
Software version 21. The survival rates were estimated with the
Kaplan-Meier Method.
Associations and interactions were also investigated by the
MDR method [15] using default settings.
Bayesian statistical methods. In our previous studies, the
application of the BN-BMLA were explained in details [39]. Here,
we briefly summarize the essence of the method.
Table 1. Characteristics of cases and controls.
Cases Controls
Gender (%)
Male 308 (56.7) 305 (57.7)
Female 235 (43.3) 224 (42.3)
Years of age at
diagnosis
Mean (6SD) 6.4(64.2) 16.1(612.4)
Median (Range) 5.1(1–18) 12.5(1.5–59)
Risk category (%)
Low risk, LR 96 (17.7) -
Medium risk, MR 309 (56.9) -
High risk, HR 55 (10.1) -
Morphological
subgroup (%)
B-ALL 390 (71.8) -
T-ALL 78 (14.4) -
Cytogenetics
Hyperdiploidy 79 (14.5) -
doi:10.1371/journal.pone.0069843.t001
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The BN-BMLA method applies a Bayesian approach, which
means that it computes the a posteriori probability of the strongly
relevant variable sets with respect to a target variable (e.g. the
variable describing the case/control status of the patients in a
genetic association study) [17]. The strongly relevant variables
have a direct influence on the target. In other words, these
variables probabilistically shield the target from the effect of other
variables. The a posteriori probability of the strong relevance (posterior)
ranges from 0 to 1 and a posterior of 1 means that the target (e.g.
immunophenotypes of ALL) definitely has a dependency relation-
ship with a predictor (e.g. SNP), whereas 0 means there is no such
relationship. Strong relevance has two types: direct relevance (e.g. a
causal SNP) and pure interaction (e.g. a SNP with an epistatic effect).
Besides strong relevance, other forms of structural associations
exist. In this context, we examined statistical interaction and
redundancy. In a structural approach, statistical interaction means
that SNPs tend to occur together more often in the model as
strongly relevant variables than it is expected according to the
assumption of their independent relevance (for details, see [17]).
On the other hand, redundancy means that two SNPs tend to be
interchangeable in strongly relevant variable sets.
The Bayesian structure based odds ratio is a recent extension to
BN-BMLA which applies a hybrid approach towards effect size
estimation by combining parametric relevance and strong
relevance aspects [40]. A Bayesian odds ratio is related to a
specific target, and it is conditioned on corresponding dependency
models (i.e. graph structures representing the interactions of
strongly relevant variables). The result is a posterior distribution
over odds ratios, which provides a finer characterization of effect
size and allows a more detailed analysis than a conventional
confidence interval. Credible intervals (i.e. Bayesian analogue of
confidence intervals) were computed based on the 95% HPD (high
probability density) region of the Bayesian odds ratio.
Table 2. List of polymorphisms investigated in this study.
Gene SNP ID Position1 Function2
ABCB1 rs10280101 chr7:86991521 intron
rs1202179 chr7:87042215 intron
rs2235013 chr7:87016562 intron
rs9282564 chr7:87067376 missense,Asn.Asp
DHFR rs11742668 chr5:79975660 intron
rs1222809 chr5:79953273 unknown
rs12517451 chr5:79955829 near-gene-3
rs1478834 chr5:79985331 intron
rs1650723 chr5:79957786 near-gene-3
rs1677626 chr5:79985201 intron
FPGS rs10106 chr9:129615896 untranslated-3
rs1544105 chr9:129602546 unknown
rs4451422 chr9:129616418 near-gene-3
GGH rs10957267 chr8:64106805 intron
rs11545078 chr8:64101318 missense, Thr.Ile
rs3780127 chr8:64103693 intron
rs719235 chr8:64114235 near-gene-5
GSTP1 rs1695 chr11:67109265 missense,Ile.Val
rs749174 chr11:67109829 intron
rs7941395 chr11:67103993 unknown
MTHFD1 rs1076991 chr14:63924794 near-gene-5
rs1950902 chr14:63952133 missense,Lys.Arg
rs2236225 chr14:63978598 missense, Arg.Gln
rs745686 chr14:64000385 near-gene-5
MTHFR rs13306561 chr1:11788391 intron
rs1801131 chr1:11777063 missense,Glu.Ala
rs1801133 chr1:11778965 missense,Ala.Val
MTRR rs10380 chr5:7950191 missense,His.Tyr
rs1532268 chr5:7931179 missense,Ser.Leu
rs162036 chr5:7938959 missense,Lys.Arg
rs1801394 chr5:7923973 missense,Ile.Met
rs2966952 chr5:7921030 near-gene-5
rs326120 chr5:7927847 intron
rs3776455 chr5:7949511 intron
MTR rs10925257 chr1:235112783 intron
rs12759827 chr1:235038809 intron
rs1805087 chr1:235115123 missense,Asp.Gly
rs2853523 chr1:235128821 untranslated-3
rs3768142 chr1:235095187 intron
rs4659724 chr1:235040747 intron
SHMT1 rs1979277 chr17:18172821 missense,Leu.Phe
rs643333 chr17:18207764 near-gene-5
rs9909104 chr17:18188746 intron
SLC19A13 rs1051266 chr21:45782222 missense,His.Arg
rs4819128 chr21:45774077 intron
rs7499 chr21:45756756 untranslated-3
SLC22A8 rs2276299 chr11:62523007 coding-
synon,Thr.Thr
rs3809069 chr11:62540348 near-gene-5
rs4149183 chr11:62522445 intron
Table 2. Cont.
Gene SNP ID Position1 Function2
SLCO1B14 rs10841769 chr12:21286286 unknown
rs11045818 chr12:21221028 coding-
synon,Ser.Ser
rs11045819 chr12:21221080 missense,Pro.Thr
rs11045823 chr12:21225012 intron
rs17328763 chr12:21173837 near-gene-5
rs4149056 chr12:21222816 missense,Val.Ala
rs4363657 chr12:21259989 intron
TPMT rs2518463 chr6:18251748 intron
rs2842951 chr6:18243662 intron
rs4449636 chr6:18255998 intron
TYMS rs1004474 chr18:650383 intron
rs2612100 chr18:662363 intron
rs2853533 chr18:648064 intron
rs2853741 chr18:647352 near-gene-5
rs9967368 chr18:646020 near-gene-5
1Position according to NCBI Genome Build 36.0;
2Function according to the UCSC Genome Browser http://genome.ucsc.edu/
(Accessed: 2013 Jun 20.);
3RFC= SLC19A1;
4SLCO1B1 = SLC21A6.
doi:10.1371/journal.pone.0069843.t002
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Results
Frequentist statistical analysis
The influences of the 64 polymorphisms in the folate pathway
on the risk of childhood acute lymphoid leukemia (ALL) were
investigated.
Out of the 67 germline polymorphisms, 64 were statistically
evaluated since two of them were monomorphic (rs12937300
SHMT1, rs1128503 ABCB1, not listed in Table 2), and one of
them did not comply with the Hardy-Weinberg Equilibrium
(HWE) (rs2032582 ABCB1, not listed in Table 2). Table S2 shows
the results of the HWE and the association tests to ALL risk for all
SNPs.
To examine the genotype frequencies in patient and control
groups, we carried out gender adjusted logistic regression analyses
on the full cohort and on various subgroups.
All the genotype and minor allele frequencies (MAF) for the
investigated polymorphisms are reported in Table S3.
The frequentist statistical analysis revealed that 9 SNPs
(rs2235013, rs12517451, rs1544105, rs1076991, rs12759827,
rs9909104, rs2853533, rs3776455, rs1532268) in 8 genes (ABCB1,
DHFR, FPGS, MTHFD1, MTR, SHMT1, TYMS, MTRR) reached
the p,0.05 values (Table S4), but due to the multiple testing,
statistical corrections were applied. In this way 2 SNPs of the
MTHFD1 and MTRR genes reached the FDR = 5% (p#1.21E-03)
significance threshold (see Table 3).
The genotype distribution of the MTHFD1 rs1076991 differed
significantly between the overall ALL and control population
(p = 1.94E-04; OR = 1.94 (1.37–2.76) for the GG genotype;
power = 0.64). Subsequently, it was investigated whether this
SNP was associated with the clinical characteristics of ALL. As can
be seen in Table 3 the GG genotype increased the risk of B-cell
ALL (p = 3.52E-04; OR = 2.00 (1.37–2.94); power = 0.59), but not
of T-cell, or HD-ALL. Further evaluation of these results showed
that the G allele positivity increased significantly the susceptibility
to ALL both in allelic (50% vs. 41.8%; p = 1.30E-04; OR = 1.39
(1.18–1.65) and genotype levels (AA vs. AG/GG; p = 4.90E-04;
OR = 1.61 (1.23–2.10)). Analyzing the ALL subgroups separately
showed that this SNP increased the risk exclusively to the B-cell
ALL.
The frequency of the MTRR rs3776455 GG genotype differed
between the ALL and control population (p = 4.49E-03;
OR = 0.57 (0.38–0.84); power = 0.51). Further analysis of the
genotype distribution showed that the GG genotype was
associated with a significantly reduced risk to ALL (AA/AG vs.
GG; p = 1.21E-03; OR = 0.55 (0.38–0.79)).
Haplotype analysis and Linkage Disequilibrium test
Haplotype analyses were carried out to study the influence of
haplotype blocks of genes on ALL risk. Two haploblocks in the
MTHFD1 gene were found to influence the risk of ALL in our
population. The ACTA haplotype (Table 4) had a slightly
protective effect against ALL (p = 0.003; OR = 0.74 (0.61–0.90)).
Table 3. Summary of the significant results of the frequentist-based statistical analyses.
Type of analysis Overall B-ALL T-ALL HD
a-ALL
pb OR (95%CI) pb OR (95%CI) pb OR (95%CI) pb OR (95%CI)
rs1076991 (MTHFD1)
Genotype
frequency
AA Reference
AG 0.01 1.49(1.12–1.97) 0.01 1.52(1.12–2.08) 0.29 1.37(0.77–2.43) 0.77 1.08(0.63–1.85)
GG 1.94E–04 1.94(1.37–2.76) 3.52E–04 2.01(1.37–2.94) 0.07 1.90(0.96–3.76) 0.66 1.17(0.59–2.33)
Allele positivity AA vs AG/GG 4.90E–04 1.61(1.23–2.1) 8.84E–04 1.65(1.23–2.22) 0.14 1.51(0.88–2.59) 0.70 1.11(0.67–1.83)
AA/AG vs GG 0.01 1.51(1.12–2.03) 0.01 1.53(1.11–2.12) 0.13 1.56(0.88–2.76) 0.72 1.12(0.67–2.04)
Allele frequency A vs G 1.30E–04 1.39(1.18–1.65) 2.10E–04 1.42(1.18–1.71) 0.08 1.36(0.97–1.90) 0.65 1.08(0.77–1.51)
rs3776455 (MTRR)
Genotype
frequency
AA Reference
AG 0.57 1.08(0.83–1.40) 0.79 1.04(0.78–1.38) 0.14 1.48(0.88–2.48) 0.43 1.22(0.74–2.02)
GG 4.49E–03 0.57(0.38–0.84) 0.01 0.57(0.37–0.87) 0.26 0.61(0.26–1.45) 0.01 0.15(0.04–0.65)
Allele positivity AA vs AG/GG 0.57 0.93(0.73–1.19) 0.46 0.90(0.69–1.18) 0.42 1.23(0.74–2.02) 0.73 0.92(0.56–1.50)
AA/AG vs GG 1.21E–03 0.55(0.38–0.79) 0.01 0.56(0.37–0.83) 0.09 0.49(0.22–1.11) 0.01 0.14(0.03–0.57)
Allele frequency A vs G 0.04 0.83(0.69–0.99) 0.04 0.82(0.67–0.99) 0.70 0.93(0.66–1.32) 0.05 0.69(0.48–1.01)
aHD: Hyperdiploid ALL;
bp-values in bold reached the p#1.21E-03;
FDR(a) = 5.0% significant threshold.
doi:10.1371/journal.pone.0069843.t003
Table 4. Estimated haplotype frequencies in the MTHFD1
gene in ALL and control population.
Haplotype ALL Control p OR (95% C.I.)
MTHFD1(rs1076991,rs1950902, rs2236225,rs745686)
ACTA 248 (23%) 302 (29%) 0.003 0.74 (0.61–
0.90)
GCCA 181 (17%) 134 (13%) 0.009 1.38 (1.08–
1.76)
doi:10.1371/journal.pone.0069843.t004
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In contrast, people carrying the GCCA haploblock, had 1.38 fold
greater risk (p = 0.009; OR = 1.38 (1.08–1.76)) to ALL (Table 4).
Linkage disequilibrium coefficients (D’, and r2 Table S5) were
calculated for each of the significant SNPs in both genes
(MTHFD1 rs1076991, MTRR rs3776455) and found that the
rs3776455 SNP in MTRR gene, was in strong linkage with other
six SNPs (rs2966952, rs1801394, rs326120, rs1532268, rs162036,
and rs10380) in the gene. It suggests that the rs3776455 SNP can
determine the status of the other six SNPs, and thus can be
regarded as a tagSNP.
Effect of the investigated SNPs on the survival rates of
the Hungarian ALL population
Earlier we have already reported the survival rate of this
population in more details [41]. In summary, the overall survival
rate was 85.5%, while the event-free survival rate was 81.0% in
this pediatric ALL population.
The logrank test was used to estimate whether these SNPs
influenced the overall or the event-free survival rates. An
association between the overall survival rates and the rs9909104
SNP in the SHMT1 gene was observed (Table 5). Overall survival
of patients with TC (80.2%) was significantly lower than the
survival of the patients with major TT (88.8%) genotype (p = 0.01).
Bayesian analysis of relevance and effect size
Strongly relevant SNPs and genes. We used the BN-
BMLA method to infer the posterior probability of strong
relevance of the genetic markers with respect to ALL susceptibility.
The SNPs and genes with the highest posterior probability of
strong relevance according to the BN-BMLA method are shown in
Table 6 (see Table S6 for all SNPs). Similarly to the frequentist
analysis, the most relevant SNP in ALL susceptibility was the
rs1076991 of the MTHFD1 gene with a posteriori probability of
strong relevance of 0.65. In B-cell lineage sample group, the
probability of the strong relevance was 0.53, while in the T-cell
lineage sample group, this probability was 0.13, and in the
hyperdiploid sample group it was nearly zero. This means, that the
evaluation with the BN-BMLA confirmed the results of the
frequentist analysis, i.e. this SNP influenced the risk exclusively of
the B-cell ALL. Furthermore, we validated these results with
MDR. It selected rs1076991 of the MTHFD1 as the best
univariate model for explaining ALL in the B-cell sample group
and in the whole sample group with overall accuracy values
0.5513 and 0.5486 respectively. In case of the hyperdiploid and T-
cell sample group rs1076991 was ranked as less relevant.
In the hyperdiploid sample group, the relevant SNPs were
rs3776455 and rs1532268 in the MTRR gene (probability of strong
relevance to HD-ALL was 0.76 and 0.68, respectively), and
rs1004474 in TYMS (0.66). The SNP rs3776455 in the MTRR
Table 5. Influence of the rs9909104 (SHMT1) polymorphism on the overall and event-free survival time in ALL.
Case processing summary Means*
Coding Total no. Events Censored Percent Estimate Std.error 95% C.I. Chi2 p
Overall survival
Wild 303 34 269 88.8% 16.2 0.3 15.6–16.9 6.4 4.0E-02
Carrier 177 35 142 80.2% 14.6 0.5 13.6–15.5
Mutant 31 5 26 83.9% 11.7 0.8 10.2–13.2
Overall 511 74 437 85.5% 15.7 0.3 15.2–16.2
Event-free survival
Wild 303 49 254 83.8% 15.4 0.4 14.7–16.1 3.2 2.0E-01
Carrier 177 40 137 77.4% 14.0 0.5 13.0–15.1
Mutant 31 6 25 80.6% 11.2 0.9 9.5–12.9
Overall 511 95 416 81.4% 15.0 0.3 14.4–15.6
*Log Rank Test (Mantel-Cox).
doi:10.1371/journal.pone.0069843.t005
Table 6. Probability of strong relevance of the most relevant variables in different sample groups according to the BN-BMLA.
Variables ALL susceptibility B-ALL susceptibility T-ALL susceptibility HD-ALL susceptibility
Gender 0.01 0.05 0.71 0.05
rs1076991 MTHFD1 0.65 0.53 0.13 0.00
rs1004474 TYMS 0.00 0.00 0.26 0.66
rs1532268 MTRR 0.00 0.03 0.21 0.68
rs3776455 MTRR 0.35 0.08 0.02 0.76
rs1222809 DHFR 0.00 0.01 0.12 0.43
rs11545078 GGH 0.03 0.06 0.16 0.33
rs3780127 GGH 0.03 0.06 0.16 0.33
doi:10.1371/journal.pone.0069843.t006
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gene was selected as the best univariate model by MDR with an
overall accuracy score of 0.5724. MDR found the other two SNPs
relevant only in interaction as described later. A few other SNPs
also showed low probabilities of relevance in ALL susceptibility
(see Figure 2).
Detailed characterization of association relations
In recent publications we described the characteristics and the
calculation of the different structural features of the different
dependency types between the variables calculated by BN-BMLA
[39,41]. The features are also summarized in Table S7 of this
paper and the results of the present study are shown in Table S8.
According to the BN-BMLA the probability that rs2236225 and
rs745686 in the MTHFD1 gene were associated to ALL
susceptibility was 0.71, but their probabilities of strong relevance
to ALL were nearly zero while the value of their transitive
relevance was 0.61, meaning that this association is probably
mediated by the direct relevance of rs1076991 in the MTHFD1
gene. The situation is the same in the case of MTRR gene, where
all measured SNPs (rs2966952, rs1801394, rs326120, rs1532268,
rs162036, rs3776455 and rs10380) had around 0.65 probability of
being associated to ALL, but only rs3776455 had a moderately
high probability of strong relevance, meaning that the associations
were mainly affected through this SNP.
In the B-cell lineage sample group, three SNPs (rs1076991,
rs2236225 and rs745686) in MTHFD1 gene showed association to
ALL with probabilities between 0.57–0.67, mediated by
rs1076991. Both in the overall ALL and the B-cell lineage sample
groups, all investigated SNPs in SLCO1B1 (SLC21A6) were
associated to ALL with probabilities between 0.51–0.55, while
the probabilities of the direct relevance of these SNPs were below
0.25. This means that in the case of this gene the exact structural
characteristics of the relations between these SNPs and the B-cell
ALL risk could not be determined but these results indicated a
possible role of this gene in the disease.
In the case of the T-cell lineage sample group the SNPs in
TYMS gene showed a relatively high probability of association
(between 0.64–0.74), but only rs2853533 and rs1004474 SNPs had
moderately high value of strong relevance, meaning that the
associations were mediated through these SNPs.
Similarly to the above detailed explanations, in the hyperdiploid
sample group, the SNPs in the TYMS gene were related to HD-
ALL with probabilities of 0.72–0.77 mediated through the effect of
rs1004474; and SNPs in MTRR (rs2966952, rs1801394, rs326120,
rs162036 and rs10380) were associated (0.79–0.82) via rs1532268
and rs3776455 (Table S8).
Structural interactions, statistical interactions and
redundancies
We examined different types of interactions, namely structural
interactions, statistical interactions and redundancies between the
strongly relevant variables. In cases of the overall, B- and T-cell
lineage sample groups, the analyses revealed no pure interactional
effect (see explanations in Table S7), i.e. the probability of pure
Figure 2. Illustration of different dependency relations between relevant SNPs and hyperdiploid ALL susceptibility. Top panel: An
interactional map including hyperdiploid ALL susceptibility (red node) and strongly relevant SNPs with respect to it (other nodes). The width of the
edges is proportional to their a posteriori probability. The directed edges represent only probabilistic relationships between the variables which are
not necessary causal. Bottom panel: The posterior probability of strong relevance (blue columns), edge (direct strong relevance, red columns), pure
interaction (green columns) and association (purple columns) of the variables to hyperdiploid ALL susceptibility according to the BN-BMLA method.
doi:10.1371/journal.pone.0069843.g002
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interaction was below ,0.2 in case of all SNPs in these sample
groups.
However, in the hyperdiploid sample group some SNPs had
moderately high probabilities for pure interaction (e.g. 0.68 in case
of rs1532268 in MTRR). Figure 2 shows the complex structural
interactional map and the probabilities of the different structural
association types of the relevant SNPs with respect to hyperdiploid
ALL susceptibility. The SNPs rs1532268 in MTRR, rs1222809 in
DHFR, rs11545078 and rs3780127 in GGH were in pure
interaction with hyperdiploid ALL through rs1004474 in TYMS.
Note, that directed edges represent only probabilistic relationships
between the variables which are not necessary causal.
In accordance with this, the interaction graph stated that for
example rs1532268 in the MTRR gene was conditionally
independent of hyperdiploid ALL, but knowing the genotype of
rs1004474 in TYMS rendered it dependent. Therefore, the values
of rs1004474 and its ‘‘parent’’ SNPs’ in the graph had a joint effect
on the value of hyperdiploid ALL without a marginal effect of the
‘‘parents’’.
We also analyzed the interaction of these SNPs with MDR. The
interaction of SNPs rs1532268 in MTRR and rs1004474 in TYMS
was among the top 10 models containing two variables with an
overall accuracy score of 0.612 (the best model had 0.6239). MDR
showed that the SNPs rs1222809 in DHFR, rs11545078 and
rs3780127 in GGH were relevant only in models containing three
variables. These models consisted of the previously discussed
interacting SNPs rs1532268 in MTRR and rs1004474 in TYMS
and one of the following additional terms: rs1222809 in DHFR,
rs11545078 and rs3780127 in GGH with accuracy scores 0.6513,
0.6566 and 0.6566, respectively (whereas the best model with
three elements had 0.6842).
We computed the statistical interactions and redundancies
between all variables in case of all sample groups. Figure 3 shows
the results in a graphical form. A statistical interaction means that
two (or more) SNPs tend to occur together more often in the
hypotheses of the strongly relevant variable sets than it is expected
(i.e. the joint strong relevance of the SNPs is more probable than it
is expected). On the other hand, redundancy means that two SNPs
Figure 3. Redundancies and interactions according to the BN-BMLA method. The figure shows the magnitude of redundancies (blue
curved lines) and interactions (red curved lines) between the variables in the overall (i.e. ALL susceptibility, A panel), in the B-cell lineage (B panel), in
the T-cell lineage (C panel) and in the hyperdiploid patient group (D panel) according to the BN-BMLA method. The width of the curved lines is
proportional to the strength of the effect. The a posteriori probability of the strong relevance of the variables is proportional to the length of the dark
red columns next to the variable in the inner gray colored ring. The corresponding genes and chromosomes of the SNPs are shown on the outer ring.
doi:10.1371/journal.pone.0069843.g003
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are somewhat interchangeable in the hypotheses of the strongly
relevant variable sets (i.e. the probability of the joint strong
relevance of the SNPs is lower than it is expected).
In the whole patient group, rs1076991 in MTHFD1 and
rs3776455 in MTRR showed a weak redundancy (Redundancy
ratio (RR) = 0.12, see Figure 3A). In the B-cell lineage sample
group, rs1076991 in MTHFD1 showed a weak redundancy with
several SNPs in SLCO1B1, namely rs17328763 (RR = 0.24),
rs11045819 (RR = 0.16), rs11045818 (RR = 0.13) and
rs11045823 (RR = 0.11). See Figure 3B for a graphical represen-
tation.
In case of the T cell lineage sample group, the gender showed a
weak redundancy with rs10925257 in MTR (RR = 0.11, see
Figure 3C).
SNPs in the structurally interacting component described above
also had a strong statistical interaction in the hypotheses of the
strongly relevant variable sets in hyperdiploid ALL (see Figure 3D).
This component involved rs1004474 in TYMS, rs1532268 in
MTRR, rs1222809 in DHFR, and one of the two SNPs rs11545078
and rs3780127 in GGH (interaction ratio (IR) = 1.14, including
rs11545078; and IR = 1.12, including rs3780127). In line with this,
the two SNPs in GGH showed a strong redundancy (RR = 0.85). It
must be noted, however, that this dataset was relatively small, thus
the exact characterization of these effects needs further validation.
Bayesian effect size analysis
Bayesian odds ratios and corresponding credible intervals were
investigated for relevant SNPs in order to characterize their effect
on ALL.
In case of MTHFD1 rs1076991 the results confirmed its
significant effect on the susceptibility to ALL. Both the AG and
the GG genotype increased the risk of ALL with credible intervals
of (1.44–1.52) and (1.88–2.01), respectively (see Table 7). The
related posterior distribution curves were highly peaked (see Figure
S1) meaning that all possible dependency models of factors
supported that MTHFD1 rs1076991 had a strong effect on ALL
based on the overall population. This effect could also be observed
in case of B-cell ALL patients. The credible intervals were similarly
narrow (AG: 1.49–1.55, GG: 1.96–2.11), and the posterior
distribution curves of the Bayesian odds ratios were similarly
peaked. For T-cell ALL patients the MTHFD1 rs1076991 had a
similar effect although not as significant as in the previous cases.
The posterior distribution curve was flat indicating that different
dependency models entailed somewhat different odds ratios (see
Figure S1). Consequently, credible intervals were relatively wider
(AG: 1.38–1.68, GG: 1.79–2.08). In contrast, the effect of
MTHFD1 rs1076991 was negligible in the HD-ALL subgroup.
The other SNP that was revealed to have a significant effect on
the susceptibility to ALL was MTRR rs3776455. Based on the
whole sample group the posterior distribution of its Bayesian odds
ratio had multiple local maxima, resulting in disjoint credible
intervals both for the AG (0.62–0.71, 0.96–1.13, 1.22–1.3) and the
GG (0.34–0.6, 0.73–0.99, 1.25–1.39) genotypes (see Figure S1 and
Table 7). This means that possible dependency models could be
divided into three groups each supporting different odds ratios. In
case of the AG genotype the majority of the models (75%)
supported the neutral odds ratio with a credible interval of (0.96–
1.13) which signified a non-relevant effect with relatively high
probability. In case of the GG genotype however, the interval of
(0.34–0.6) had the majority support of dependency models (84%),
which confirmed the protective effect of the GG genotype with a
high probability. On the other hand, the credible interval showing
increased risk (1.25–1.39) also had some support (9%). This
phenomenon might explain earlier results indicating the GG
genotype as risk factor. Although the current study population
indicates a protective effect, it is possible that the risk increasing
effect could be observed under different circumstances.
A similar structural uncertainty could be observed in the case of
B-cell ALL patients, although the posterior distribution of
Bayesian odds ratios was only bimodal. The effect of AG genotype
of MTRR rs3776465 was neutral (0.99–1.04) with moderately high
probability (0.75), whereas the GG genotype had a protective
effect (0.53–0.54) with a similar probability (0.75). In contrast, in
the HD-ALL subgroup the related Bayesian odds ratios of MTRR
rs3776465 indicated strong effects with narrow credible intervals.
The AG genotype increased the risk of HD-ALL (1.2–1.27), while
the GG genotype had a remarkable protective effect (0.09–0.2).
The interaction between TYMS rs1004474 and MTRR
rs1532268 shown in Figure 2 were also further investigated in
this respect. On one hand, the TYMS rs1004474 had a negligible
effect on the risk of HD-ALL both in case of GA and GG
genotypes (with respect to AA) with credible intervals of (0.75–
0.97) and (0.94–1.10) respectively (Figure S2). On the other hand,
both the GA and AA genotypes of MTRR rs1532268 led to a
Table 7. Credible intervals (95%) corresponding to the Bayesian odds ratios of MTHFD1 rs1076991 and MTRR rs3776455.
ALL B-ALL T-ALL
95% CR-L 95% CR-U Prob. weight 95% CR-L 95% CR-U Prob. weight 95% CR-L 95% CR-U Prob. weight
Bayesian odds ratios of rs1076991 (MTHFD1)
AG vs AA 1.44 1.53 100% 1.48 1.56 100% 1.38 1.68 100%
GG vs AA 1.88 2.01 100% 1.96 2.11 100% 1.79 2.08 100%
Bayesian odds ratios of rs3776455 (MTRR)
AG vs AA 0.62 0.71 7% 0.99 1.04 75% 1.19 1.27 100%
0.96 1.13 75% 1.33 1.39 25%
1.22 1.3 18%
GG vs AA 0.34 0.6 84% 0.53 0.54 75% 0.09 0.2 100%
0.73 0.99 7% 1.3 1.56 25%
1.25 1.39 9%
CR: credible interval, a Bayesian analogue of the confidence interval, 95% CR-U and CR-L: upper and lower thresholds of the 95% credible interval.
doi:10.1371/journal.pone.0069843.t007
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slightly increased risk to HD-ALL (1.28–1.40 and 0.97–1.72 with
respect to GG), however the credible interval of the latter was
exceedingly wide (Figure S2). The joint Bayesian odds ratio of
TYMS rs1004474 and MTRR rs1532268 was computed by
parametric averaging in a dominant model (Table S9). Remark-
ably, the combination of rs1004474 (AA) - rs1532268 (GG) (i.e. the
common homozygous case for both SNPs) had the highest
conditional probability of risk of HD-ALL, namely 0.23, which
exceeded the individual effect of risk allele A for MTRR rs1532268
with a conditional probability of risk of 0.14. Note, that whereas
the univariate analysis indicated an increased risk for the carriers
of the MTRR rs1532268 A allele, the multivariate analysis revealed
a more complex pattern of interaction: the MTRR rs1532268 A
allele became protective in carriers of the AA genotype of the
TYMS rs1004474 with a joint OR of 0.32 (Table S9).
Discussion
In this study we investigated the associations of 67 SNPs in 15
genes in the folate metabolic pathway with the development of
childhood ALL and whether they influenced the survival rates of
the patients. Beside the traditional statistical methods, we also
evaluated our results with the BN-BMLA method.
Altogether 9 SNPs (rs2235013, rs12517451, rs1544105,
rs1076991, rs12759827, rs9909104, rs2853533, rs3776455,
rs1532268) in 8 genes (ABCB1, DHFR, FPGS, MTHFD1, MTR,
SHMT1, TYMS, MTRR) showed nominally significant association
with the risk to ALL.
After the correction for multiple testing 2 SNPs of the MTHFD1
and MTRR genes reached the significance threshold and a SNP in
the SHMT1 gene influenced the survival rate of the patients. We
also demonstrated the additional information provided by the BN-
BMLA method in relation to the traditional frequentist evaluation
methods.
The two most frequently investigated non-synonym SNPs in the
MTHFR gene, the rs1801133 (C677T, Ala222Val) and the
rs1801131 (A1298C, Glu429Ala) did not show any association
with the susceptibility to ALL or with the survival rates of the
patients in our population. Although there are several reports
showing associations between these polymorphisms and ALL risk
[8,42,43], or survival [23], our results correspond to the results of a
meta-analysis where the pooled odds ratio for these two variants
did not show association with ALL risk [44], and also to some
recent and relatively large studies, where neither SNPs showed
association [26,27]. In these papers it is also discussed in details
what the explanations for these inconsistent findings can be.
MTHFD1 is one of the major components of the folate
pathway. It is a trifunctional enzyme which catalyzes the
conversion of tetrahydrofolate. The enzyme and its derivatives
are important cofactors for de novo purine, pyrimidine and
methionine synthesis [6,8,45]. In our study we found an
association between rs1076991 polymorphism in the MTHFD1
gene and B-cell ALL risk. The G allele significantly increased the
risk to the disease especially in homozygous form. The rs1076991
SNP is located in the promoter region of the gene. Using a
luciferase reporter gene assay, Carroll et al. found a significant
effect of this polymorphism on the MTHFD1 promoter activity.
The construct with A allele had only 38% of the activity than that
of with the G allele (T and C alleles in the original paper [28], but
they are A/G according to the official databases, like dbSNP, and
we use this nomenclature). Although in this paper a bioinformatic
analysis did not reveal an alteration of any consensus transcription
factor binding site that would explain the observed difference in
activity between the two genotypes, this result means that the G
allele could be associated with a higher MTHFD1 gene expression
level in vivo. Presently, it can not be explained, how an elevated
MTHFD1 enzyme level can be associated with an increased risk to
B-cell ALL. A plausible explanation can be, that elevated level of
MTHFD1 can lead to a decrease availability of its substrate, 5,10-
methylenetetrahydrofolate, resulting in lower rate of synthesis of
deoxythymidine monophosphate from deoxyuridine monophos-
phate and therefore increasing the risk of uracil incorporation and
chromosomal damage.
The non-synonymous rs2236225 (G1958A; arg653gln) poly-
morphism of the MTHFD1 gene has been widely studied in
different traits including ALL [8,12,29,30]. In the present study we
did not find any associations, which involved this variant, except
two haplotypes based on 4 SNPs in the MTHFD1 gene. But,
according to the structures of the haplotypes, it is very probable,
that the main signal responsible for this association came from the
rs1076991 SNP, rather than from the rs2236225, because the
haplotype with the rs1076991 G allele was associated with
increased, while with the A allele with decreased risk to ALL.
The other significant association of this study is the decreased B-
cell ALL risk associated with the GG genotype of the rs3776455
SNP in the MTRR gene. The gene codes for the methionine
synthase reductase enzyme which plays an important role in the
folate pathway. The methylation of homocysteine to methionine is
catalyzed by MTR (methionine synthase) using vitamin B12 as a
cofactor, in which the MTR may become inactivated due to the
oxidation of vitamin B12 cofactor. MTRR could catalyze
reductive methylation of vitamin B12 by using SAM as a methyl
donor, leading to the activation of MTR.
Presently, there is no information about the possible function of
the SNP. It does not change consensus sequence, and it has not
earlier been identified as a phenotype influencing variant. The
most studied SNP in the MTRR gene is the rs1801394, which
causes a non-synonym isoleucine-to-methionine change at position
22 (A66G). The variant enzyme has a lower affinity for MTR [31]
and some studies have reported elevated homocysteine levels for
carriers of the homozygote wild-type genotype (AA) compared to
other genotypes, while others have not [46–48]. Some studies
found an association between A66G genotype and decreased risk
to ALL, but a meta-analysis provided no evidence for an
association [11]. In our study we have not revealed an association
between rs1801394 and ALL risk, although it showed some
linkage to the associated rs3776455 SNP. Similarly, in our
population the rs3776455 SNP was in linkage to other SNPs, like
rs162036, rs10380, which have earlier been found to be associated
with 3-fold elevated risk for spina bifida [49]. In our study we have
found association only between the rs3776455 and reduced risk to
B-cell and HD-ALL. Further studies are needed to reveal how this
SNP or variants in linkage can influence the risk to the disease.
The rs9909104 SNP in the SHMT1 gene was weakly associated
with a reduced risk to ALL and the minor allele in homozygous
form with a reduced survival rate. Methotrexate (MTX) is an
important part of the ALL chemotherapy. It is an antifolate drug
and polymorphisms in the folate pathway probably influence the
response to and toxicity of the MTX therapy. Our result is in line
with those, which showed that variants in the folate pathway
associated with decreased disease risk are often associated with
poorer response to MTX therapy [33,34,50]. SHMT1 has the
same substrate as MTHFD1 and MTHFR (5,10-methylenetetra-
hydrofolate), thus they are in competition for this substrate. The
most frequently studied SNP in the SHMT1 gene is the rs1979277
(1420G/A), which earlier has been found to be associated with
decreased MTX sensitivity in pediatric ALL [35]. We also
genotyped this SNP, but found no such connection. This SNP is
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in strong linkage with the associated rs9909104 (D’ = 1), however,
because the rs1979277 A allele is more frequent, thus the r2 is only
0.13, it means that the linkage is partly one-sided, i.e. the
rs9909104 C allele always occurs together with the rs1979277 A
allele, but in the other way it is not true. That can be the
explanation how it is possible, that the rs9909104 SNP is
associated with a reduced survival rate in our population, and
possible with decreased MTX response, but the rs1979277 SNP
did not. Because in the study of de Jonge et al [35], the rs9909104
SNP was not genotyped, it could also be hypothesized, that the
signal in that study came also from the non-genotyped rs9909104
SNP linked with the rs1979277. It must be added, however, that
rs1979277 SNP is a non-synonym variation (L474F) in the coding
region of the gene, while until now no function has been associated
with the rs9909104 SNP.
Next to the frequentist-based analysis, we also evaluated our
results with the BN-BMLA method. We showed in our previous
papers [39,41], as well as in the present study, that BN-BMLA is
capable of identifying not only those variants, which are directly
associated with the target value, but also variants whose effects are
mediated, or are only in interactions. In addition, because BN-
BMLA uses a different approach than the traditional methods, and
the Bayesian statistics offer an automated and normative solution
for the multiple hypothesis testing problems [16,17], the method
can also be used as an alternative method for confirmation of the
results. Earlier, we have tested the BN-BMLA method in a case-
control setup using artificial datasets for identifying interactions
and conditional relevance [51]. The BN-BMLA was proven to be
superior over other multivariate methods using conditional models
designed to detect associations between genotypic variables and
the target variable.
In the present study BN-BMLA confirmed the role of the
rs1076991 SNP in the MTHFD1 gene, since it showed strong
relevance to B-cell ALL and that of the rs3776455 in the MTRR
which showed strong relevance to HD-ALL and association to
ALL. The two SNPs also showed a slight redundancy, implying
that they have similar, although independent effect.
The main strength of the BN-BMLA is that it can suggest
multivariate structural features of the different dependency types
between the variables. In this dataset such structural features could
only be revealed in HD-ALL. It is contrary to the expectations,
since one would have thought that polymorphisms in genes in an
important metabolic pathway, which has been shown to have a
role in the pathogenesis of ALL, must be in interactions. A possible
explanation can be that the effect sizes of the particular
interactions are too low and larger populations would be needed
for their detection. HD-ALL might have a more homogenous
genetic background, than B-cell or T-cell ALL, and thus detection
of it required smaller population. Similar findings have been
experienced in our previous study [41].
A particular feature of the gene-gene interactions was also
revealed by the BN-BMLA. Certain genotypes of the MTRR
rs1532268 SNP were associated with a slightly increased risk to
HD-ALL, while they turned to be protective when occurred
together with a given allele of a gene (TYMS) in the same
metabolic pathway. Logically, this can especially happen, when a
pathway, like the folate, is responsible for a sensitive balance of
several important metabolites. Variations in this pathway can lead
to both accumulation and depletion of these metabolites leading to
different consequences. This result also suggests a possible reason
for the inconclusive results of the different studies investigating
only the effect of single SNPs, and shows the importance of the
systems biologic approach.
Similarly to the previous studies, the BN-BMLA named further
genes like TYMS, DHFR, GGH and SNPs, and also provided
possible explanations, what their roles could be in the gene-gene
interactions. The results were also confirmed by MDR, a statistical
method frequently used for detecting multiple interactions [14].
Naturally, however, all of these findings must be verified in in vitro
studies, although it will not be an easy task.
The heterogeneous results in the different subtypes of the ALL
shown in Figure 3, also confirm the notion that ALL is not one
disease, but rather several diseases with different pathogeneses, but
with similar symptoms, and therapeutic possibilities. If we can
reveal the differences in the pathogeneses, there can be a chance
for more personalized and thus more effective therapies.
This study has several strengths and limitations. First, although
our sample set contains similar rate of relapsed patients to what
was observed in the whole population [33]. The rate of died
patients, however, is lower in our study population. Patients who
died during the chemotherapy due to therapy resistant progressive
disease or due to infections or toxicities of therapy are
underrepresented in our sample.
It is well known that association studies suffer from a possibility of
false positive results. To reduce this possibility we applied multiple
test correction and also the BN-BMLA method, which offers an
automated and normative solution for the multiple hypothesis
testing problems [16]. But, as was discussed earlier, because of the
possible low effect sizes of the SNPs a larger population would have
been required for detecting genetic interactions. To overcome this,
meta-analyses or an international leukemia consortium can be a
solution. Our group is also a member of The International
Childhood Acute Lymphoblastic Leukaemia Genetics Consortium
[52], and participated in similar studies [53]. But meta-analyses and
studies based on international consortia suffer from problems
caused by populations with heterogeneous genetic background and
significantly different environmental conditions. It was shown that
even a given genetic background could respond oppositely in
different environments [54,55]. The number of patients in this study
is one of the largest ones relative to the population of the country
(Hungary) compared to other studies [35]. One of the main strength
of this study is the relatively large population with homogeneous
ethnicity and environment. It can be one of the main reasons, that
contrary to most studies where after multiple testing correction no
significant associations could have been found, here we could
present significant results even after the correction [26,34,35,56]. It
must be noted, however, that in this paper we discussed mainly
those results, which remained significant after the multiple testing
correction, or had.0.5 a posteriori probability in the BN-BMLA.
But in this study we also detected a number of other nominally
significant associations, which most other studies regarded as real
associations, and discussed accordingly. Thus, our other results
presented in supplementary tables can also be involved, and
analyzed in subsequent meta-analyses. Furthermore, the power
analysis in our study indicated the potential advantage of more
samples to confirm the status of the non-significantly associated
SNPs, particularly in case of non-replicating SNPs reported in other
studies (e.g. rs1801133 - MTHFR, rs1801131 - MTHFR, rs2236225
– MTHFD1, rs1801394 - MTRR, rs1979277 – SHMT1).
In conclusion, in our study population the rs1076991 SNP in
the MTHFD1 gene and the rs3776455 in the MTRR gene
significantly influenced the risk of ALL. The heterozygous form of
the rs9909104 SNP in the SHMT1 gene was associated with a
lower survival rate. Next to these results several other SNPs in
different genes in the folate metabolic pathway showed nominally
significant associations with altered risk of ALL. The results were
also evaluated by the BN-BMLA method, which confirmed the
Role of Variations of Folate Pathway in All Risk
PLOS ONE | www.plosone.org 11 August 2013 | Volume 8 | Issue 8 | e69843
main findings and detected structural features of the different
dependency types between the SNPs in the hyperdiploid subtype
of ALL. These results give further evidence that polymorphisms in
the folate pathway can influence the ALL risk and the effectiveness
of the therapy. We also showed several advantageous features of
the BN-BMLA method, and we demonstrated that in gene
association studies it might be useful supplementary to traditional
frequentist statistical methods. The tool is available at a public
website [57].
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